A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of the Oral sGC stImulator Vericiguat to Improve Physical Functioning in Activities of Daily Living in Patients With Heart Failure and Preserved Ejection Fraction (VITALITY-HFpEF)
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008420/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in
patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical
limitation score) compared to placebo after 24 weeks of treatment.
提供机构：
Vivli
创建时间：
2022-09-02
